Daewoong's Subsidiary Daewoong Pharmaceutical Extends Nabota Plant 3 Construction Investment Period by One Year to Secure Production Capacity
Daewoong's subsidiary Daewoong Pharmaceutical has extended the end date of its new facility investment for Nabota Plant 3 construction from June 30, 2026 to May 31, 2027, a one-year delay.
The total investment amount remains KRW 101.36 billion, representing 13.7% of equity, aimed at entering the neurotoxin therapeutic market and securing production capacity.
The amendment resets the termination date based on the expected GMP approval date for actual operation rather than the building completion date, with further amendments to follow if schedule changes occur.
[AI Summary]The extension of the investment period for Daewoong's subsidiary's facility construction reflects a delay in the original timeline, but with no change in investment amount and the purpose of securing production capacity intact, the impact on shareholder value is limited.
KOSPI Filing Information
[Correction of Description] Investment In New Facilities, Etc. (Major Management Matters Of Subsidiaries)